Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von Videoplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name Youtube
Zweck Externe Medien

Selected Publications

The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies.
Becker JP, Riemer AB.
Frontiers in Immunology 2022, 13: 883989.

The shared frameshift mutation landscape of MSI cancers suggests immunoediting during tumor evolution.
Ballhausen A*, Przybilla MJ*, Jendrusch M*, Haupt S, Pfaffendorf E, Seidler F, Witt J, Hernandez-Sanchez A, Urban K, Draxlbauer M, Krausert S, Ahadova A, Kalteis MS, Pfuderer P, Heid D, Stichel D, Gebert J, Bonsack M, Schott S, Bläker H, Seppälä T, Mecklin J-P, Ten Broeke S, Nielsen M, Heuveline V, Krzykalla J, Benner A, Riemer AB, von Knebel Doeberitz M, Kloor M. * Equal contributors.
Nature Communications 2020, 11(1): 4740.

Inducing immunity where it matters: orthotopic HPV tumor models and therapeutic vaccinations.
Zottnick S, Voß AL, Riemer AB.
Frontiers in Immunology 2020, 11: 1750.

Enhanced radiation sensitivity of human papillomavirus-driven head and neck cancer: focus on immunological aspects.
Özcan-Wahlbrink M, Schifflers C, Riemer AB.
Frontiers in Immunology 2019, 10: 2831.

Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding data set.
Bonsack M*, Hoppe S*, Winter J, Tichy D, Zeller C, Küpper MD, Schitter EC, Blatnik R, Riemer AB. * Equal contributors.
Cancer Immunology Research 2019, 7(5): 719-736.

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.
Kruse S, Büchler M, Uhl P, Sauter M, Scherer P, Lan TCT, Zottnick S, Klevenz A, Yang R, Rösl F, Mier W, Riemer AB.
OncoImmunology 2018, 8(1): e1524694.

A targeted LC-MS strategy for low-abundant HLA class-I-presented peptide detection identifies novel human papillomavirus T-cell epitopes.
Blatnik R*, Mohan N*, Bonsack M*, Falkenby LG, Hoppe S, Josef K, Steinbach A, Becker S, Nadler WM, Rucevic M, Larsen MR, Salek M, Riemer AB. * Equal contributors.
Proteomics 2018, 18(11): e1700390.

Immune evasion mechanisms of human papillomavirus: an update.
Steinbach A, Riemer AB.
International Journal of Cancer 2018, 142(2): 224-229.

ERAP1 overexpression in HPV-induced malignancies:  a possible novel immune evasion mechanism.
Steinbach A, Winter J, Reuschenbach M, Blatnik R, Klevenz A, Bertrand M, Hoppe S, von Knebel Doeberitz M, Grabowska AK, Riemer AB.
OncoImmunology 2017, 6(7): e1336594.

Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK, Kaufmann AM, Riemer AB.
International Journal of Cancer 2015, 136(1): 212-24.

HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology.
Zhang GL, Riemer AB, Keskin DB, Chitkushev L, Reinherz EL, Brusic V.
Database 2014, article ID bau031; doi:10.1093/database/bau031

Therapeutic vaccine strategies against HPV.
Khallouf H, Grabowska AK, Riemer AB.
Vaccines 2014, 2(2):422-462.

The invisible enemy – how human papillomaviruses avoid recognition and clearance by the host immune system.
Grabowska AK & Riemer AB.
Open Virology Journal 2012, 6: 249-56.


 

Full Bibliography

Original Articles, First or Senior Author

Light contamination in stable isotope-labelled internal peptide standards is frequent and a potential source of false discovery and quantitation error in proteomics.
Salek M*, Förster JD*, Lehmann WD, Riemer AB. * Equal contributors.
Analytical and Bioanalytical Chemistry 2022, 414(8): 2545-2552.

Inducing immunity where it matters: orthotopic HPV tumor models and therapeutic vaccinations.
Zottnick S, Voß AL, Riemer AB.
Frontiers in Immunology 2020, 11: 1750.

Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding data set.
Bonsack M*, Hoppe S*, Winter J, Tichy D, Zeller C, Küpper MD, Schitter EC, Blatnik R, Riemer AB. * Equal contributors.
Cancer Immunology Research 2019, 7(5): 719-736.

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.
Kruse S, Büchler M, Uhl P, Sauter M, Scherer P, Lan TCT, Zottnick S, Klevenz A, Yang R, Rösl F, Mier W, Riemer AB.
OncoImmunology 2018, 8(1): e1524694.

A targeted LC-MS strategy for low-abundant HLA class-I-presented peptide detection identifies novel human papillomavirus T-cell epitopes.
Blatnik R*, Mohan N*, Bonsack M*, Falkenby LG, Hoppe S, Josef K, Steinbach A, Becker S, Nadler WM, Rucevic M, Larsen MR, Salek M, Riemer AB. * Equal contributors.
Proteomics 2018, 18(11): e1700390.

ERAP1 overexpression in HPV-induced malignancies:  a possible novel immune evasion mechanism.
Steinbach A, Winter J, Reuschenbach M, Blatnik R, Klevenz A, Bertrand M, Hoppe S, von Knebel Doeberitz M, Grabowska AK, Riemer AB.
OncoImmunology 2017, 6(7): e1336594.

Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK, Kaufmann AM, Riemer AB.
International Journal of Cancer 2015, 136(1): 212-24.

Identification and validation of reference genes for expression studies in human keratinocyte cell lines treated with and without interferon-γ – a method for qRT-PCR reference gene determination.
Riemer AB, Keskin DB, Reinherz EL.
Experimental Dermatology 2012, 21(8): 625-9.

A conserved E7-derived CTL epitope expressed on human papillomavirus-16 transformed HLA-A2+ human epithelial cancers.
Riemer AB, Keskin DB, Zhang G, Handley M, Anderson KS, Brusic V, Reinhold B, Reinherz EL.
The Journal of Biological Chemistry 2010, 285(38): 29608-22.

Supression of gastric acid increases the risk of developing Immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model.
Riemer AB, Gruber S, Pali-Schöll I, Kinaciyan K, Untersmayr E, Jensen-Jarolim E.
Clinical and Experimental Allergy 2010, 40(3): 486-93.

Active induction of tumor-specific IgE antibodies by oral mimotope vaccination.
Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E.
Cancer Research, 2007 67(7): 3406-11.

Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
Riemer AB, Förster-Waldl E, Brämswig KH, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E.
European Journal of Immunology 2006, 36(5): 1267-74.

Isolation and structural analysis of peptide mimotopes of the disialoganglioside GD2, a neuroblastoma tumor antigen.
Förster-Waldl E*, Riemer AB*, Dehof AK, Neumann D, Brämswig K, Boltz-Nitulescu G, Pehamberger H, Zielinski CC, Scheiner O, Pollak A, Lode H, Jensen-Jarolim E. * Equal contributors.
Molecular Immunology 2005, 42(3): 319-325.

Vaccination with cetuximab mimotopes and biological properties of induced anti-EGFR antibodies.
Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.
The Journal of the National Cancer Institute 2005, 97(22): 1663-70.

High-molecular weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E.
Cancer Immunology Immunotherapy 2005, 54(7): 677-84.

Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition.
Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E.
Molecular Immunology 2005, 42(9): 1121-1124.

Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E.
The Journal of Immunology 2004, 173(1): 394-401.

Original Articles, Co-Author

The shared frameshift mutation landscape of MSI cancers suggests immunoediting during tumor evolution.
Ballhausen A*, Przybilla MJ*, Jendrusch M*, Haupt S, Pfaffendorf E, Seidler F, Witt J, Hernandez-Sanchez A, Urban K, Draxlbauer M, Krausert S, Ahadova A, Kalteis MS, Pfuderer P, Heid D, Stichel D, Gebert J, Bonsack M, Schott S, Bläker H, Seppälä T, Mecklin J-P, Ten Broeke S, Nielsen M, Heuveline V, Krzykalla J, Benner A, Riemer AB, von Knebel Doeberitz M, Kloor M. * Equal contributors.
Nature Communications 2020, 11(1): 4740.

High-throughput prediction of MHC class I and class II neoantigens with MHCnuggets.
Shao XM, Bhattacharya R, Huang J, Sivakumar IKA, Tokheim C, Zheng L, Hirsch D, Kaminow B, Omdahl A, Bonsack M, Riemer AB, Velculescu VE, Anagnostou V, Pagel KA, Karchin R.
Cancer Immunology Research 2020, 8(3): 396-408.

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo.
Vormehr M, Reinhard K, Blatnik R, Josef K, Beck JD, Salomon N, Suchan M, Selmi A, Vascotto F, Zerweck J, Wenschuh H, Diken M, Kreiter S, Türeci Ö, Riemer AB, Sahin U.
OncoImmunology 2018, 8(3): 1553478.

MHCflurry: Open-source class I MHC binding affinity prediction.
O'Donnell TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U, Hammerbacher J.
Cell Systems 2018, 7(1): 129-132.e4.

Peptide processing is critical for T-cell memory inflation and may be optimized to improve immune protection by CMV-based vaccine vectors.
Dekhtiarenko I, Ratts RB, Blatnik R, Lee LN, Fischer S, Borkner L, Oduro JD, Marandu TF, Hoppe S, Ruzsics Z, Sonnemann JK, Mansouri M, Meyer C, Lemmermann NA, Holtappels R, Arens R, Klenerman P, Früh K, Reddehase MJ, Riemer AB, Cicin-Sain L.
PLoS Pathogens 2016,12(12): e1006072.

Analysis of major histocompatibility complex-bound HIV peptides identified from various cell types reveals common nested peptides and novel T cell responses.
Rucevic M, Kourjian G, Boucau J, Blatnik R, Garcia Bertran W, Berberich MJ, Walker BD, Riemer AB, Le Gall S.
Journal of Virology 2016, 90(19): 8605-20.

A vaccine targeting mutant IDH1 induces antitumor immunity.
Schumacher T, Bunse L, Sahm F, Pusch S, Quandt J, Wiestler B, Oezen I, Menn O, Osswald M, Grabowska AK, Eichmueller S, Riemer AB, Friese M, Beckhove P, von Deimling A, Wick W, Ott M, Keil M, Balss J, Rauschenbach K, Vogler I, Diekmann J, Sahin U, Stevanovic S, Trautwein N, Okun J, Platten M.
Nature 2014, 512(7514): 324-7.

HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology.
Zhang GL, Riemer AB, Keskin DB, Chitkushev L, Reinherz EL, Brusic V.
Database 2014, article ID bau031; doi:10.1093/database/bau031

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer.
Anderson KS, Wong J, D’Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M.
British Journal of Cancer 2011, 104(12): 1896-905.

Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells.
Anderson KS, Zeng W, Sasada T, Choi J, Riemer AB, Su M, Drakoulakos D, Kang YJ, Brusic V, Wu C, Reinherz EL.
Cancer Immunology Immunotherapy 2011, 60(6): 857-67.

3,3’,4,4’,5,5’-Hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V, Schicher N, Szekeres T, Jäger W, Elbling L, Riemer AB, Scheiner O, Trimurtulu G, Venkateswarlu S, Mikula M, Swoboda A, Fiebiger E, Gerner C, Pehamberger H, Kunstfeld R.
Journal of Investigative Dermatology 2010, 130(6): 1668-79.

Aluminum per se and in the anti-acid drug sucralfate promotes sensitization via the oral route.
Brunner R, Wallmann J, Szalai K, Karagiannis P, Altmeppen H, Riemer AB, Scheiner O, Jensen-Jarolim E, Pali-Schöll I.
Allergy, 64(6): 890-7.

Immunization with mimotopes prevents growth of CEA-positive tumors in BALB/c mice.
Brämswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E.
Clinical Cancer Research 2007, 13(21): 6501-8.

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.
Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, S. Jaeger IS, Preissner R, Förster-Waldl E, Jensen-Jarolim E, Lode HN.
Cancer Research 2006, 66(21): 10567-75.

Mimotopes identify conformational epitopes on parvalbumin, the major fish allergen.
Untersmayr E, Szalai K, Riemer AB, Hemmer W, Swoboda I, Hantusch B, Schöll I, Spitzauer S, Scheiner O, Jarisch R, Boltz-Nitulescu G, Jensen-Jarolim E.
Molecular Immunology 2006, 43(9): 1454-61.

Occupational sensitization to ribosome-inactivating proteins (RIPs) in researchers.
Szalai K, Schöll I, Förster-Waldl E, Polito L, Bolognesi A, Untersmayr E, Riemer AB, Boltz-Nitulescu G, Stirpe F, Jensen-Jarolim E.
Clinical and Experimental Allergy 2005, 35(10): 1354-60.

Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight-melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity.
Hafner C, Wagner S, Allwardt D, Riemer AB, Scheiner O, Pehamberger H, Breiteneder H.
Melanoma Research 2005, 15(2): 111-7.

Anti-ulcer drugs promote IgE formation towards dietary antigens in adult patients.
Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. FASEB J. 2005, 19(6): 656-8.
Epub 2005 Jan 25 (10.1096/fj.04-3170fje).

Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice.
Untersmayr E, Schöll I, Swoboda I, Beil WJ, Förster-Waldl E, Walter F, Riemer A, Kraml G, Kinaciyan T, Spitzauer S, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E.
Journal of Allergy and Clinical Immunology 2003, 112(3): 616-23.

 

Review Articles & Commentaries

The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies.
Becker JP, Riemer AB.
Frontiers in Immunology 2022, 13: 883989.

Bacterial peptides presented on tumour cells could be immunotherapy targets.
Riemer AB.
Nature 2021, 592(7852): 28-29.

Enhanced radiation sensitivity of human papillomavirus-driven head and neck cancer: focus on immunological aspects.
Özcan-Wahlbrink M, Schifflers C, Riemer AB.
Frontiers in Immunology 2019, 10: 2831.

 Immunotherapy and vaccine development.
Leung C, Münz C, Riemer A.
Journal of Immunology Research 2018: 8751027.

Immune evasion mechanisms of human papillomavirus: an update.
Steinbach A, Riemer AB.
International Journal of Cancer 2018, 142(2): 224-229.

Therapeutic vaccine strategies against HPV.
Khallouf H, Grabowska AK, Riemer AB.
Vaccines 2014, 2(2): 422-462.

The invisible enemy – how human papillomaviruses avoid recognition and clearance by the host immune system.
Grabowska AK & Riemer AB.
Open Virology Journal 2012, 6: 249-56.

Impfstoffe gegen Krebs.
Riemer AB.
Spectrum Dermatologie 2009, 2: 44-46.

Mimotope vaccination – from allergy to cancer.
Knittelfelder R, Riemer AB, Jensen-Jarolim E.
Expert Opinion on Biological Therapy 2009, 9(4): 493-506.

AllergoOncology: The role of IgE-mediated allergy in cancer.
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodríguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H.
Allergy 2008, 63(10): 1255-66.

Der Einsatz von Trastuzumab in der adjuvanten und palliativen Therapie des Mammakarzinoms.
Riemer AB & Zielinski CC.
Therapeutische Umschau 2008, 65(4): 217-22.

Mimotope vaccines: Epitope mimics induce anti-cancer antibodies.
Riemer AB & Jensen-Jarolim E.
Immunology Letters 2007, 113(1): 1-5

Small mimotopes are big in identifying B-cell epitopes.
Jensen-Jarolim E & Riemer AB.
Blood 2006; 108(6): 1794-5.

Allergen mimotopes.
Riemer A, Scheiner O, Jensen-Jarolim E.
Methods 2004; 32(3): 321-7.

Book Chapters

Infektionen als Tumorursache: Virusätiologie.
Riemer AB, von Knebel Doeberitz M, Dürst M.
In: Kompendium internistische Onkologie. (Hans-Joachim Schmoll, Ed.) Springer. 5. Edition 2020 (E-Book)

Common Concepts of Immune Defense.
Roth-Walter F, Riemer AB, Jensen-Jarolim E, Stockinger H.
In: Comparative Medicine. Anatomy and Physiology. (Erika Jensen-Jarolim, Ed.) Springer. 1. Edition 2014: 219-66.

Die natürliche Abwehr.
Jensen-Jarolim E & Riemer AB.
In: Krankheit, Krankheitsursachen und -bilder (Brigitte Marian, Ed.) Facultas Universitätsverlag, Wien. 6. Edition 2012: 111-26.

to top
powered by webEdition CMS